

Date: February 06, 2026

To, BSE Limited (“BSE”), Corporate Relationship Department, 2 nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai – 400001 BSE Scrip code: 543399	To, National Stock Exchange of India Limited (“NSE”) “Exchange Plaza”, 5 th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai – 400051 NSE Symbol: TARSONS
--	---

Subject: Outcome of the Board Meeting held on Friday, February 06, 2026

Dear Sir/ Madam,

Pursuant to the provisions of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we hereby inform you that Board of Directors of Tarsons Products Limited ('the Company' or 'Tarsons') at its meeting held today, i.e., Friday, February 06, 2026, which commenced at **11:30 A.M. (IST)** and concluded at **12:10 P.M. (IST)**, have inter alia considered and approved the following transactions:

1. Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025:

We have enclosed herewith the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2025, along with the Limited Review Report of the Statutory Auditors of the Company thereon.

2. Equity infusion of further EUR 3 Million in our Wholly-Owned Subsidiary situated in Singapore:

The equity infusion of further EUR 3 Million (Three Million Euros Only) in its wholly-owned subsidiary, Tarsons Life Science Pte. Ltd., a company incorporated in Singapore for meeting its operational and financial expenses.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is attached as ***Annexure I***.

3. Appointment of Mr. Vinesh Mohan Kriplani (DIN: 08212644) as an Additional Director (Category: Non-Executive Independent Director):

Based on the recommendation of the Nomination and Remuneration Committee, the board of directors have approved the appointment Mr. Vinesh Mohan Kriplani (DIN: 08212644) as an Additional Director (Category: Non-Executive Independent Director) of the company w.e.f. February 06, 2026 for a term of five (5) consecutive years, subject to the approval of shareholders of the Company.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is attached as ***Annexure II***.

4. Resignation of Mr. Girish Paman Vanvari (DIN:07376482) as an Independent Director of the Company:

Mr. Girish Paman Vanvari (DIN:07376482) vide letter dated February 05, 2026 has tendered his resignation as an independent director of the company w.e.f. closure of business hours of February 06, 2026 due to personal commitments. Consequently, he shall also cease to be the chairperson of the Audit Committee & Risk Management Committee and member of Nomination

Remuneration Committee of the Company. The letter of resignation received from Mr. Girish Paman Vanvari is enclosed herewith as **Annexure – V**.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is attached as **Annexure III**.

5. Reconstitution of Committees of the Board:

Due to appointment of Mr. Vinesh Mohan Kriplani as Additional Director of the Company and resignation of Mr. Girish Paman Vanvari, Independent Director, of the Company, the Board of Directors has reconstituted the Audit Committee, Nomination and Remuneration Committee, and Risk Management Committee. The composition of the reconstituted committees is attached as **Annexure IV**.

The above intimations shall also be hosted on the website of the Company at www.tarsons.com.

We request you to take the above information on record.

Thanking You,

Yours Faithfully,
For Tarsons Products Limited

Santosh Kumar Agarwal
CFO, Company Secretary and Compliance Officer
ICSI Membership No. A44836

Annexure-I

Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:

Sl. No.	Particulars	Details
1.	Name of the Target Entity, details in brief such as size, turnover, etc.:	<p>Tarsons Life Science Pte. Ltd. (“Target Entity”)</p> <p>Tarsons Life Science Pte. Ltd. is a wholly-owned subsidiary of Tarsons Products Limited (“the Company”) incorporated in Singapore.</p> <p>The Turnover of the Target Entity for the F.Y. 2024-25 is Nil.</p>
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”:	<p>Tarsons Life Science Pte. Ltd. being a wholly-owned subsidiary is a related party of the Company.</p> <p>The transaction falls within the ambit of related party transaction and is at arm’s length basis.</p> <p>None of the Company’s promoter/ promoter group have any interest in Target Entity.</p> <p>Further, Mr. Aryan Sehgal, Mr. Sanjive Sehgal and Mr. Subramanian Arun Kumar are the directors of the Company hold directorship in the Target Entity.</p>
3.	Industry to which the entity being acquired belongs:	<p>Tarsons Life Science Pte. Ltd. is engaged in the Non-Operating Financial Holding Companies</p> <p>(The Target Entity is a Special Purpose Vehicle)</p>
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity):	The additional capital infusion by the Company is to fund the needs of the target entity towards repayment of existing loans, meeting the general corporate purposes and other operational & financial expenses.
5.	Brief details of any governmental or regulatory approvals required for the acquisition:	Not Applicable
6.	Indicative time period for completion of the acquisition:	The additional capital infusion to be completed in quarterly tranches on or before March 31, 2027
7.	Consideration - whether cash consideration or share swap or any other form and details of the same:	Consideration payable in cash
8.	Cost of acquisition and/or the price at which the shares are acquired:	The total consideration for the acquisition shall be based on the value determined by a registered valuer.

9.	Percentage of shareholding / control acquired and / or number of shares acquired:	No change in ownership/ percentage of shareholding. Tarsons Life Science Pte. Ltd. will continue to be a wholly-owned subsidiary of Tarsons Products Limited.						
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief):	<p>Tarsons Life Science Pte. Ltd. is a 100% subsidiary based in Singapore of Tarsons Products Limited.</p> <p>Date of incorporation: November 10, 2023.</p> <p>Country in which the acquired entity has presence: Singapore</p> <p>The last two (2) years' turnover of Tarsons Life Science Pte. Ltd. is as under:</p> <table border="1" data-bbox="807 644 1362 834"> <thead> <tr> <th>Financial Year</th> <th>Amount in EUR</th> </tr> </thead> <tbody> <tr> <td>2024-25</td> <td>Nil</td> </tr> <tr> <td>2023-24</td> <td>Nil</td> </tr> </tbody> </table> <p>Any other significant information: NIL</p>	Financial Year	Amount in EUR	2024-25	Nil	2023-24	Nil
Financial Year	Amount in EUR							
2024-25	Nil							
2023-24	Nil							

For Tarsons Products Limited

Santosh Kumar Agarwal
CFO, Company Secretary & Compliance Officer
ICSI Membership No. A44836

Annexure-II

Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:

Sl. No.	Particulars	Details
1	Reason for change viz. appointment, resignation, removal, death or otherwise	<p>Appointment</p> <p>The Board of Directors, upon the recommendation of the Nomination and Remuneration Committee, approved the appointment of Mr. Vinesh Mohan Kriplani (DIN: 08212644) as an Additional Director (Category: Non-Executive Independent Director) w.e.f. February 06, 2026 for a term of five (5) consecutive years, subject to the approval of the shareholders.</p>
2	Date of Appointment / cessation and term of appointment	February 06, 2026 for a term of five (5) consecutive years, subject to the approval of shareholders.
3	Brief Profile	<p>Mr. Vinesh Mohan Kriplani is a Chartered Accountant with over 29 years of experience in Indian corporate and international taxation, specialising in mergers and acquisitions, corporate restructuring, and cross-border transactions.</p> <p>Mr. Kriplani is currently associated with the Poonawalla Group through Serum Institute of India, where he leads M&A and international tax matters, advising senior leadership on strategic growth initiatives. His expertise spans transfer pricing, tax dispute resolution, valuations, and foreign exchange regulations.</p> <p>Mr. Kriplani has previously held senior leadership roles with Ernst & Young, KPMG, and PricewaterhouseCoopers, including serving as Senior Partner at EY India, where he built and led a market-leading tax practice. He has worked across India and Hong Kong, advising multinational clients on complex transactions. He is also a co-founder of Transaction Square LLP and has served at the Board level of a regulated NBFC, bringing a strong governance-led and investor-focused perspective.</p>
4	Disclosure of relationships between Directors	None of the Directors are related to Mr. Vinesh Mohan Kriplani, the Additional Director of the Company.
5	Information as required pursuant to BSE circular ref no. LIST/ COMP/ 14/ 2018-19 and the National Stock Exchange of India Limited with ref no. NSE/CML/2018/24, dated June 20, 2018	Mr. Kriplani is not debarred from holding the office of director pursuant to any SEBI order or any other authority

For Tarsons Products Limited

Santosh Kumar Agarwal
CFO, Company Secretary & Compliance Officer
ICSI Membership No. A44836

Annexure-III

Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:

Sl. No.	Particulars	Details
1.	Reason for change viz. appointment, resignation, removal, death or otherwise	Resignation Mr. Girish Paman Vanvari (DIN: 07376482) resigned from the Board of Directors of the Company and consecutively from the Audit Committee, Nomination and Remuneration Committee and Risk Management Committee with effect from February 06, 2026 due to personal commitments as cited in his resignation letter.
2.	Date of Appointment/ cessation and term of appointment	February 06, 2026
3.	Brief Profile	NA
4.	Disclosure of relationships between Directors	NA

Additional Information in case of resignation of an Independent Director as per Para A (7B) of Part A of Schedule III of SEBI Listing Regulations, 2015

5.	Letter of Resignation along with detailed reason for resignation	Attached as Annexure-V		
6.	Names of listed entities in which the resigning director holds directorships, indicating the category of directorship and membership of board committees, if any.	Name of the Company	Name of the Committee	Chairperson/ Member
		Aurobindo Pharma Ltd – Independent Director	Audit Committee	Chairperson
			Risk Management Committee	Chairperson
			Nomination & Remuneration Committee	Member
			Stakeholders Committee	Member
			CSR Committee	Member
		Himadri Specialty Chemical Ltd - Independent Director	Audit Committee	Chairperson
			Nomination & Remuneration Committee	Member
		Tarsons Products Ltd - Independent Director	Audit Committee	Chairperson
			Risk Management Committee	Chairperson
			Nomination & Remuneration Committee	Member

An ISO 9001 & ISO 13485 Certified Company

	<p>Rategain Travel Technologies Ltd - Independent Director</p> <p>Kolte-Patil Developers Ltd - Independent Director</p> <p>Blue Jet Healthcare Ltd - Independent Director</p>	Audit Committee	Chairperson
		Nomination & Remuneration Committee	Chairperson
		Risk Management Committee	Chairperson
		Audit Committee	Member
		Nomination & Remuneration Committee	Member
		Risk Management Committee	Member
		Audit Committee	Chairperson
		Risk Management Committee	Member
		Nomination & Remuneration Committee	Member
7.		Mr. Girish Paman Vanvari has confirmed that there are no material reasons for his resignation other than those mentioned in his resignation letter.	

For Tarsons Products Limited

Santosh Kumar Agarwal
CFO, Company Secretary & Compliance Officer
ICSI Membership No. A44836

Annexure-IV
Composition of the Committees w.e.f., February 06, 2026

Name of the Committee	Name and Designation of the Director	Committee Position
Audit Committee	Mr. Viresh Oberai Non-Executive Independent Director DIN:00524892	Chairperson
	Mr. Vinesh Kriplani Non-Executive Independent Director DIN: 08212644	Member
	Mrs. Divya Sameer Momaya Non-Executive Independent Director DIN: 00365757	Member
Nomination and Remuneration Committee	Mr. Viresh Oberai Non-Executive Independent Director DIN: 00524892	Chairperson
	Mr. Vinesh Kriplani Non-Executive Independent Director DIN: 08212644	Member
	Mrs. Divya Sameer Momaya Non-Executive - Independent Director DIN: 00365757	Member
Risk Management Committee	Mr. Viresh Oberai Non-Executive Independent Director DIN:00524892	Chairperson
	Mr. Aryan Sehgal Executive - Whole Time Director DIN: 06963013	Member
	Mr. Sanjive Sehgal Executive-Managing Director DIN: 00787232	Member

For Tarsons Products Limited

Santosh Kumar Agarwal
CFO, Company Secretary & Compliance Officer
ICSI Membership No. A44836

GIRISH VANVARI

801, Martin Nest, 9, Central Avenue, Santacruz (West), Mumbai 400 054

To,
Chairman
Board of Directors
Tarsons Products Limited
902, Martin Burn Business Park,
BP – 3, Salt Lake, Sector – V,
Kolkata – 700091, West Bengal.

Dear Sanjive,

Its been an honour to be a part of the Board of the company for the past many years. As you know my 5 year terms expires this year on May 9, 2026. Due to certain personal commitments, I would like to be relieved from the board three months earlier. Accordingly would like to resign from the Board effective February 6, 2026.

I thank the Board and management for the support and cooperation during my tenure, it has been a privilege to serve the Company, and I wish **Tarsons Product Limited** continued success.



Girish Paman Vanvari
DIN: **07376482**
Place: Mumbai
Date: 05 February 2026

Price Waterhouse Chartered Accountants LLP

Review Report

To
The Board of Directors
Tarsons Products Limited
Martin Burn Business Park,
Room No. 902, BP-3,
Salt Lake, Sector - V
Kolkata - 700 091

1. We have reviewed the consolidated unaudited financial results of Tarsons Products Limited (the "Holding Company"), its subsidiaries (the Holding Company and its subsidiaries hereinafter referred to as the "Group") (refer Note 1 on the Statement) for the quarter ended December 31, 2025 and the year to date results for the period April 1, 2025 to December 31, 2025 which are included in the accompanying 'Statement of Consolidated Unaudited Financial Results for the quarter and nine months ended December 31, 2025' (the "Statement"). The Statement is being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes.
2. This Statement, which is the responsibility of the Holding Company's Management and has been approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements ('SRE') 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Relationship	Entity Name
Holding Company	Tarsons Products Limited, India
Subsidiary (Direct)	Tarsons Life Science Pte. Ltd., Singapore
Subsidiary (Indirect)	Nerbe plus GmbH & Co. KG, Germany (Subsidiary of Tarsons Life Science Pte. Ltd., Singapore)
Subsidiary (Indirect)	Nerbe R&D GmbH, Germany (Subsidiary of Tarsons Life Science Pte. Ltd., Singapore)



Price Waterhouse Chartered Accountants LLP, Plot No. 56 & 57, Block - DN, Sector - V, Salt Lake, Kolkata - 700091, India
T: +91 (33) 44044348

Registered office and Head office: 11-A, Vishnu Digamber Marg, Sucheta Bhawan, New Delhi - 110002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

Price Waterhouse Chartered Accountants LLP

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The interim financial results of one subsidiary reflect total revenues of ₹ 239.17 million and ₹ 658.54 million, total net profit/ (loss) after tax of ₹ 7.58 million and ₹ 15.18 million and total comprehensive income/ (loss) of ₹ 7.58 million and ₹ 15.18 million, for the quarter ended December 31, 2025 and for the period from April 1, 2025 to December 31, 2025, respectively, as considered in the consolidated unaudited financial results. These interim financial results have been reviewed by other auditors, vide which they have issued an unmodified conclusion, have been furnished to us by the other auditor and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based on the reports of the other auditor and the procedures performed by us as stated in paragraph 3 above.
7. The consolidated unaudited financial results include the interim financial results of two subsidiaries which have not been reviewed by their auditors, whose interim financial results reflect total revenue of ₹ 17.04 million and ₹ 33.04 million, total net profit/ (loss) after tax of ₹ (20.29) million and ₹ (60.53) million and total comprehensive income/ (loss) of ₹ (20.29) million and ₹ (60.53) million for the quarter ended December 31, 2025 and for the period from April 1, 2025 to December 31, 2025, respectively, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter referred to in paragraphs 6 and 7 above.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016



Amit Peswani
Partner
Membership Number: 501213
UDIN: 26501213ANAIMR2146

Place: Gurugram
Date: February 6, 2026

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

(Amount in ₹ Million, unless otherwise stated)

PARTICULARS	Quarter ended			Nine months ended		Year ended
	December 31, 2025	September 30, 2025	December 31, 2024	December 31, 2025	December 31, 2024	March 31, 2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 Revenue from operations	1,078.93	1,023.29	956.77	3,015.86	2,797.23	3,924.14
2 Other income	84.22	58.04	8.49	175.62	121.81	159.60
3 Total Income (1+2)	1,163.15	1,081.33	965.26	3,191.48	2,919.04	4,083.74
4 Expenses:						
(a) Cost of materials consumed	178.93	173.47	195.84	510.48	581.53	800.36
(b) Purchase of stock in trade	142.78	104.28	111.51	353.20	392.06	510.18
(c) Changes in inventories of finished goods, work-in-progress, stock-in-trade	29.75	54.63	5.11	113.21	(58.09)	(16.11)
(d) Employee benefits expense	195.07	178.07	163.76	551.76	485.77	653.80
(e) Depreciation and amortisation expenses	250.35	224.81	174.07	674.52	424.69	624.99
(f) Other expenses	217.25	238.41	184.20	650.60	658.95	868.65
(g) Finance costs	60.47	51.75	50.29	162.93	141.83	193.86
Total Expenses	1,074.60	1,025.42	884.78	3,016.70	2,626.74	3,635.73
5 Profit before Exceptional Items and taxes (3-4)	88.55	55.91	80.48	174.78	292.30	448.01
6 Exceptional Items						
Statutory impact of new labour codes (Refer Note 4)	13.48	-	-	13.48	-	-
7 Profit before taxes (5-6)	75.07	55.91	80.48	161.30	292.30	448.01
8 Tax expense						
Current tax	25.12	22.72	25.01	61.21	85.75	148.57
Deferred tax charge / (credit)	(0.41)	(0.03)	2.88	(1.32)	10.88	1.74
Total Tax expense	24.71	22.69	27.89	59.89	96.63	150.31
9 Profit for the period / year (7-8)	50.36	33.22	52.59	101.41	195.67	297.70
10 Other comprehensive income						
Items that will be reclassified to Profit or Loss	(3.97)	(27.54)	35.37	(89.38)	9.51	(16.62)
Foreign exchange translation reserve						
Items that will not be reclassified to profit or loss						
Remeasurements of post-employment benefit obligations	(0.93)	(0.94)	(0.26)	(2.80)	(0.77)	(1.58)
Income tax on above	0.23	0.24	0.07	0.70	0.20	0.40
Total other comprehensive income/(loss) for the period/year	(4.67)	(28.24)	35.18	(91.48)	8.94	(17.80)
11 Total comprehensive income for the period / year (9+10)	45.69	4.98	87.77	9.93	204.61	279.90
12 Paid up equity share capital	106.41	106.41	106.41	106.41	106.41	106.41
13 Other equity (Including Reserves)						6,195.70
14 Earnings per equity share (Face value of ₹ 2 each) (not annualised for quarters/nine months- in ₹)						
(a) Basic	0.95	0.62	0.99	1.91	3.68	5.60
(b) Diluted	0.95	0.62	0.99	1.91	3.68	5.60

See accompanying notes to the Consolidated Unaudited Financial Results



Notes to the Consolidated Unaudited Financial Results

1 The Statement of Consolidated Unaudited Financial Results includes results of the following entities, together referred as "Group":

S No.	Name of the entity	% Shareholding as of December 31, 2025	Consolidated as
1	Tarsons Products Limited, India		Holding Company
2	Tarsons Life Science Pte. Ltd., Singapore (effective from November 10, 2023)	100	Subsidiary of Tarsons Products Limited, India
3	Nerbe plus GmbH & Co. KG, Germany (effective from January 1, 2024) (Subsidiary of Tarsons Life Science Pte. Ltd., Singapore)	100	Subsidiary of Tarsons Life Science Pte. Ltd., Singapore
4	Nerbe R&D GmbH, Germany (effective from January 1, 2024) (Subsidiary of Tarsons Life Science Pte. Ltd., Singapore)	100	Subsidiary of Tarsons Life Science Pte. Ltd., Singapore

2 The above Statement of Consolidated Unaudited Financial Results for the quarter and nine months ended December 31, 2025 ("Consolidated Financial Results") has been reviewed by the Audit Committee and then approved by the Board of Directors of the Company in their respective meetings held on February 06, 2026.

3 The aforesaid Consolidated Unaudited Financial Results has been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013, as amended (the "Act") read with relevant rules thereunder and in terms of Regulations 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

4 Effective 21 November 2025, The Government of India has consolidated multiple existing labour legislations into a unified framework comprising of four Labour Codes collectively referred to as the 'New Labour Codes'. Under Ind AS 19, changes to employee benefit plans arising from legislative amendments constitute a plan amendment, requiring recognition of past service cost immediately in the Statement of profit and Loss. The Group has assessed and disclosed the incremental impact of the New Labour Codes of Rs. 13.48 million on consolidated financial results, primarily arising due to change in definition of wages and the recognition of such past service costs. The Government is in the process of notifying related rules to the New Labour Codes and impact of these will be evaluated and accounted for in accordance with applicable accounting standards in the period in which they are notified. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Group has presented such past service cost as "Statutory impact of new Labour Codes" under "Exceptional Items" in the above consolidated financial results.

5 The Group is primarily engaged in the business of manufacturing and selling of plastic laboratory products and certain scientific instruments, which represents a single business. Operating segments have been identified based on how the Chief Operating Decision Maker (CODM) reviews and assesses the Group's performance, which is on the basis of the different geographical areas wherein major entities within the Group operate.

Particulars	Quarter ended			Nine months ended		Year ended
	December 31, 2025	September 30, 2025	December 31, 2024	December 31, 2025	December 31, 2024	March 31, 2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Segment Revenue						
India	839.77	804.87	761.51	2,357.32	2,210.99	3,141.38
Germany	239.16	218.42	195.26	658.54	586.24	782.76
Rest of the world	-	-	-	-	-	-
Total	1,078.93	1,023.29	956.77	3,015.86	2,797.23	3,924.14
Inter-segment Revenue						
India	0.11	0.21	0.11	0.43	0.34	0.39
Germany	-	-	-	-	-	-
Rest of the world	-	-	-	-	-	-
Total	0.11	0.21	0.11	0.43	0.34	0.39
Total Segment Revenue from Operations	1,079.04	1,023.50	956.88	3,016.29	2,797.57	3,924.53
Less : Intersegment Eliminations						
India	(0.11)	(0.21)	(0.11)	(0.43)	(0.34)	(0.39)
Germany	-	-	-	-	-	-
Rest of the world	-	-	-	-	-	-
Total Revenue	1,078.93	1,023.29	956.77	3,015.86	2,797.23	3,924.14
Segment results before exceptional items, interest, tax and depreciation						
India	369.78	315.17	287.89	935.14	800.99	1,211.89
Germany	27.89	15.89	19.91	73.06	65.35	66.58
Rest of the world	(0.94)	(0.82)	(5.22)	(2.79)	(13.75)	(20.55)
Less : Intersegment Eliminations						
India	-	-	0.05	-	(0.01)	-
Total Segment results before exceptional items, interest, tax and depreciation	396.73	330.24	302.63	1,005.41	852.48	1,257.92
Add: Finance income	2.64	2.23	2.21	6.82	6.34	8.94
Less: Finance cost	60.47	51.75	50.29	162.93	141.83	193.85
Less: Depreciation and amortisation	250.35	224.81	174.07	674.52	424.69	624.99
Profit/(Loss) before exceptional items and tax	88.55	55.91	80.48	174.78	292.30	448.01
Less: Exceptional item	13.48	-	-	13.48	-	-
Profit/(Loss) before tax	75.07	55.91	80.48	161.30	292.30	448.01
Less: Tax expense	24.71	22.69	27.89	59.89	96.63	150.31
Profit/(Loss) for the period/year	50.36	33.22	52.59	101.41	195.67	297.70
Segment assets						
India	10,947.21	10,769.39	9,619.75	10,947.21	9,619.75	9,906.28
Germany	1,230.23	1,217.29	1,169.75	1,230.23	1,169.75	1,195.50
Rest of the world	1,187.91	1,154.72	1,038.04	1,187.91	1,038.04	1,055.74
Less : Intersegment Eliminations	(1,578.74)	(1,504.12)	(1,555.45)	(1,578.74)	(1,555.45)	(1,357.12)
Total Assets	11,786.60	11,637.28	10,272.09	11,786.60	10,272.09	10,800.40
Segment liabilities						
India	4,253.48	4,145.93	3,252.54	4,253.48	3,252.54	3,382.39
Germany	625.03	612.50	537.21	625.03	537.21	587.52
Rest of the world	984.93	1,246.70	1,159.45	984.93	1,159.45	1,100.01
Less : Intersegment Eliminations	(388.91)	(634.19)	(903.95)	(388.91)	(903.95)	(571.63)
Total Liabilities	5,474.54	5,370.94	4,045.25	5,474.54	4,045.25	4,498.29

For and on behalf of the Board of Directors of Tarsons Products Limited



Aryan Sehgal
Whole-Time Director
DIN: 06963013



Price Waterhouse Chartered Accountants LLP

Review Report

To
The Board of Directors
Tarsons Products Limited
Martin Burn Business Park,
Room No. 902, BP-3,
Salt Lake, Sector - V
Kolkata - 700 091

1. We have reviewed the standalone unaudited financial results of Tarsons Products Limited (the "Company") for the quarter ended December 31, 2025 and the year to date results for the period April 1, 2025 to December 31, 2025, which are included in the accompanying 'Statement of Standalone Unaudited Financial Results for the quarter and nine months ended December 31, 2025' (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016



Amit Peswani
Partner
Membership Number : 501213
UDIN : 26501213JLHXRS9796

Place : Gurugram
Date : February 6, 2026

Price Waterhouse Chartered Accountants LLP, Plot No. 56 & 57, Block - DN, Sector - V, Salt Lake, Kolkata - 700091, India
T: +91 (33) 44044348

Registered office and Head office: 11-A, Vishnu Digamber Marg, Sucheta Bhawan, New Delhi - 110002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

(Amount in ₹ Million, unless otherwise stated)

PARTICULARS	Quarter ended			Nine months ended		Year ended
	December 31, 2025	September 30, 2025	December 31, 2024	December 31, 2025	December 31, 2024	March 31, 2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 Revenue from operations	839.88	805.08	761.62	2,357.75	2,211.33	3,141.77
2 Other income	97.13	73.16	21.22	216.12	176.34	240.06
3 Total Income (1+2)	937.01	878.24	782.84	2,573.87	2,387.67	3,381.83
4 Expenses:						
(a) Cost of materials consumed	178.93	173.47	195.85	510.48	581.53	800.36
(b) Purchase of stock in trade	20.88	23.02	22.37	62.42	78.09	114.91
(c) Changes in inventories of finished goods, work-in-progress, stock-in-trade	43.04	22.10	0.88	92.62	(30.69)	(21.76)
(d) Employee benefits expense	116.96	118.20	111.13	353.98	327.01	437.89
(e) Depreciation and amortisation expenses	226.52	201.73	156.11	605.77	365.31	540.11
(f) Other expenses	188.68	206.82	152.24	563.11	571.04	756.37
(g) Finance costs	53.20	44.14	41.27	140.14	130.09	175.24
Total Expenses	828.21	789.48	679.85	2,328.52	2,022.38	2,803.12
5 Profit before Exceptional Items and taxes (3-4)	108.80	88.76	102.99	245.35	365.29	578.71
6 Exceptional Items						
Statutory impact of new labour codes (Refer Note 4)	13.48	-	-	13.48	-	-
7 Profit before taxes (5-6)	95.32	88.76	102.99	231.87	365.29	578.71
8 Tax expense						
Current tax	23.57	22.29	22.76	57.59	80.73	144.78
Deferred tax charge	0.81	1.20	4.10	2.34	14.54	6.62
Total Tax expense	24.38	23.49	26.86	59.93	95.27	151.40
9 Profit for the period / year (7-8)	70.94	65.27	76.13	171.94	270.02	427.31
10 Other comprehensive income						
Items that will not be reclassified to profit or loss						
Remeasurements of post-employment benefit obligations	(1.88)	(0.94)	(0.25)	(2.80)	(0.76)	(1.58)
Income tax on above	0.48	0.24	0.06	0.70	0.19	0.40
Total other comprehensive income/(loss) for the period/year	(1.40)	(0.70)	(0.19)	(2.10)	(0.57)	(1.18)
11 Total comprehensive income for the period / year (9+10)	69.54	64.57	75.94	169.84	269.45	426.13
12 Paid up equity share capital	106.41	106.41	106.41	106.41	106.41	106.41
13 Other equity (Including Reserves)						6,417.48
14 Earnings per equity share (Face value of ₹ 2 each) (not annualised for quarters/nine months- in ₹)						
(a) Basic	1.33	1.23	1.43	3.23	5.07	8.03
(b) Diluted	1.33	1.23	1.43	3.23	5.07	8.03

See accompanying notes to the Standalone Unaudited Financial Results



Notes to the Standalone Unaudited Financial Results

- 1 The above Statement of Standalone Unaudited Financial Results for the quarter and nine months ended December 31, 2025 ("Standalone Financial Results") of Tarsons Products Limited ('the Company') has been reviewed by the Audit Committee and then approved by the Board of Directors of the Company in their respective meetings held on February 6, 2026.
- 2 The aforesaid Standalone Financial Results has been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013, as amended (the "Act") read with relevant rules thereunder and in terms of Regulations 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
- 3 The Company is primarily engaged in the business of manufacturing and selling of plastic laboratory products and certain scientific instruments, which represents a single business. The Board of Directors ("Chief Operating Decision Maker" or "CODM") reviews the financial results when making decisions about allocating resources and assessing performance of the Company as a whole and hence, the Company has concluded that the Company constitutes a single segment as per Ind AS 108 'Operating Segments'.
- 4 Effective 21 November 2025, The Government of India has consolidated multiple existing labour legislations into a unified framework comprising of four Labour Codes collectively referred to as the 'New Labour Codes'. Under Ind AS 19, changes to employee benefit plans arising from legislative amendments constitute a plan amendment, requiring recognition of past service cost immediately in the Statement of profit and Loss. The Company has assessed and disclosed the incremental impact of the New Labour Codes of Rs. 13.48 million on standalone financial results, primarily arising due to change in definition of wages and the recognition of such past service costs. The Government is in the process of notifying related rules to the New Labour Codes and impact of these will be evaluated and accounted for in accordance with applicable accounting standards in the period in which they are notified. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Company has presented such past service cost as "Statutory impact of new Labour Codes" under "Exceptional Items" in the above standalone financial results.

For and on behalf of the Board of Directors of Tarsons Products Limited



Aryan Sehgal
Whole-Time Director
DIN: 06963013



Date: February 6, 2026
Place: Kolkata